Skip to main content Skip to main menu
UF Health University of Florida

College of Pharmacy

UNIVERSITY of FLORIDA

APPLY TO PHARM.D. PROGRAM
Marco Mottinelli

Marco Mottinelli

Assistant Scientist

Department: Medicinal Chemistry
Business Phone: (352) 273-7714
Business Email: m.mottinelli@cop.ufl.edu
CV: View Curriculum Vitae

About Marco Mottinelli

Marco Mottinelli received his master’s degree in Chemistry and Pharmaceutical Technology at the University of Pisa, Italy. After graduating, he spent one year at DSM pharmaceutical products, the Netherlands, before moving to the University of Bath, England to pursue his Doctorate degree in medicinal chemistry. Upon completion of his Ph.D. on the synthesis and biological evaluation of novel chemical entities targeting estrogen biosynthesis and signaling for the treatment of breast cancer, Mottinelli moved to the University of Mississippi as a postdoctoral associate within the group of Dr. Christopher McCurdy. In 2017, Dr. Mottinelli joined the University of Florida as a postdoctoral research associate in the department of Medicinal Chemistry and in 2020 he obtained the Research Assistant position. His research focuses on the development of neurotherapeutics in the areas of pain and drug of abuse and more specifically on Neuropeptide FF receptor and Sigma receptors ligands.

Publications

2021
N-Phenyl-1,2,3,4-tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17β-Hydroxysteroid Dehydrogenase 1 Inhibitors.
ChemMedChem. 16(1):259-291 [DOI] 10.1002/cmdc.202000762. [PMID] 33151004.
View on: PubMed Publisher’s Site
2020
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics. [DOI] 10.1124/jpet.120.000189. [PMID] 33384303.
View on: PubMed Publisher’s Site
2020
Evaluation of 18F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue.
Theranostics. 10(18):7938-7955 [DOI] 10.7150/thno.47585. [PMID] 32724451.
View on: PubMed Publisher’s Site
2019
Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives.
The Journal of pharmacology and experimental therapeutics. 368(2):272-281 [DOI] 10.1124/jpet.118.253484. [PMID] 30530624.
View on: PubMed Publisher’s Site
2019
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain.
Frontiers in pharmacology. 10 [DOI] 10.3389/fphar.2019.00678. [PMID] 31258480.
View on: PubMed Publisher’s Site
2019
Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1134-1135 [DOI] 10.1016/j.jchromb.2019.121875. [PMID] 31790916.
View on: PubMed Publisher’s Site
2017
Accessing simply-substituted 4-hydroxytetrahydroisoquinolines via Pomeranz-Fritsch-Bobbitt reaction with non-activated and moderately-activated systems.
Beilstein journal of organic chemistry. 13:1871-1878 [DOI] 10.3762/bjoc.13.182. [PMID] 29062406.
View on: PubMed Publisher’s Site
2011
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5.
Bioorganic & medicinal chemistry letters. 21(24):7331-6 [DOI] 10.1016/j.bmcl.2011.10.031. [PMID] 22056743.
View on: PubMed Publisher’s Site

Teaching Profile

Courses Taught
2020-2021
PHA6447 Drug Design

Contact Details

Phones:
Business:
(352) 273-7714
Emails:
Business:
m.mottinelli@cop.ufl.edu